Search

Find exactly what you’re looking for.
Search

Showing 1-7 of 7 results
​On February 2, 2023, the Illinois Supreme Court weighed in and answered a question that had previously remained uncertain and hotly contested in recent years: how long is the statute of limitations for claims under the Illinois Biometric Information Privacy Act (“BIPA”)? According to the Supreme...

BOSTON, MA (February 7, 2023) – Jon Barooshian and Patrick Tracey bring a combined five decades of experience as litigators to their new roles as partners in the firm’s Boston office. Mr. Barooshian will focus his practice on white collar and government enforcement matters and tax controversies...

​The FTC has announced the annual updates to the Hart-Scott-Rodino (“HSR”) size thresholds, fees and the daily penalty for HSR violations. The updated thresholds and fees were published in the Federal Register on January 26, 2023 and will take effect on February 27, 2023. See Federal Register...
LATEST UPDATE The FTC has voted to extend the public comment period on its proposed rule to ban employers from imposing non-competes on their workers, and will now be accepting comments on the proposed rule until April 19, 2023. Comments can still be submitted in either writing or online using the...
​ Class Action Lawsuits Stemming From Use of Session Replay Software Are on the Rise In an effort to enhance customer experience, many businesses and institutions have their public-facing websites collect information with the use of cookies, web beacons, chat bots, and/or “session replay” software...

(Washington, DC, July 21, 2021) – Earl Adams, Jr., co-chair of the firm’s Regulatory, Compliance and Government practice, and Managing Partner of the firm’s Washington, D.C. office, has been appointed by President Biden to serve as Chief Counsel to the Federal Motor Carrier Safety Administration (...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information
Contact us